Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement 
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
Dyadic Announces Continued Listing on the Nasdaq Capital Market
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
Dyadic Expands IP Protection and Business Development Activities in Japan

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.